Osteomalacia

disease
On this page

Also known as osteomalacia (disease)

Summary

Osteomalacia (MONDO:0001068) is a disease and 13 clinical trials. Top therapeutic interventions include cholecalciferol and edotreotide gallium ga-68. A subtype of bone remodeling disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameosteomalacia
Mondo IDMONDO:0001068
MeSHD010018
DOIDDOID:10573
NCITC26838
SNOMED CT4598005
UMLSC0029442
MedGen14533
Is cancer (heuristic)no

Also known as: osteomalacia · osteomalacia (disease)

Data availability: 1 HPO phenotype · 6 cell lines.

Disease family

This is a subtype of bone remodeling disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorderskeletal system disorderbone disorderbone remodeling diseaseosteomalacia

Related subtypes (5): bone resorption disease, fibrous dysplasia, hyperostosis, osteosclerosis, rickets

Subtypes (1): Oncogenic osteomalacia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
BurosumabApproved (phase 4)

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
InfigratinibPhase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified10
PHASE41
PHASE1/PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01025128PHASE4COMPLETEDVitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density
NCT03736564PHASE1/PHASE2COMPLETEDGa-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
NCT01748812PHASE1TERMINATEDCinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
NCT00024804Not specifiedRECRUITINGA Natural History Study of Bone and Mineral Disorders
NCT00001242Not specifiedCOMPLETEDStudies of States With Resistance to Vitamin D and Parathyroid Hormone
NCT00099762Not specifiedCOMPLETEDCatheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia
NCT01102751Not specifiedCOMPLETEDSerum FGF-23 and Vitamin D Deficiency
NCT02084693Not specifiedCOMPLETEDCOMPREHENSIVE® REVERSE SHOULDER Mini BasePlate
NCT02252679Not specifiedCOMPLETEDStudy of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders
NCT02548520Not specifiedCOMPLETEDMaternal and Infant Vitamin Status During the First Nine Months of Infant Life
NCT04045834Not specifiedUNKNOWNStudy of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia
NCT04841213Not specifiedCOMPLETEDDental Implants Rehabilitation in Patients With Vitamin D3 Imbalance
NCT05716750Not specifiedUNKNOWNSerum Prolidase Activity and the Role of Leptin in Osteomalacia

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CHOLECALCIFEROL41
EDOTREOTIDE GALLIUM GA-6841